STOCK TITAN

[SCHEDULE 13G] Indivior Pharmaceuticals, Inc. Passive Investment Disclosure (>5%)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Indivior Pharmaceuticals Schedule 13G: Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 4,806,556 shares of Common Stock, representing 3.8% of the class. The filing states that after acquiring beneficial ownership of more than 5% on March 17, 2026, the reporting persons ceased to be beneficial owners of more than 5% by the date of this filing.

The reported shares are held by entities subject to voting and investment discretion by Millennium Management LLC and related managers. A Joint Filing Agreement dated March 20, 2026 is attached and signatures are provided by the reporting persons.

Positive

  • None.

Negative

  • None.

Insights

Large manager reports a sub‑5% stake after a transient >5% position.

The filing lists 4,806,556 shares and 3.8% as the reported beneficial ownership figures tied to Millennium entities and Israel A. Englander. The filing also states a prior >5% position on March 17, 2026.

Timing and cash‑flow treatment are not described in this excerpt; subsequent filings or issuer disclosures would clarify whether holdings changed due to purchases, dispositions, or share count adjustments.

Joint filing and shared voting/dispositive power are the key governance signals here.

The report attributes shared voting power and shared dispositive power of 4,806,556 shares to the reporting group, and includes a Joint Filing Agreement dated March 20, 2026. Signatures include the reporting persons and counsel.

These disclosures clarify group coordination; any governance or vote‑blocking implications depend on total outstanding shares, which are not stated in the provided excerpt.






45579U109

(CUSIP Number)
03/17/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:03/20/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:03/20/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:03/20/2026
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of March 20, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

Indivior Pharmaceuticals Inc.

NASDAQ:INDV

View INDV Stock Overview

INDV Rankings

INDV Latest News

INDV Latest SEC Filings

INDV Stock Data

3.68B
120.07M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NORTH CHESTERFIELD